Mxi1, a Myc Antagonist, Suppresses Proliferation of DU145 Human Prostate Cells

Mary M. Taj,1 Rana J. Tawil,1 Lars D. Engstrom,1 Zhi Zeng,2 Clara Hwang,2 Martin G. Sanda,2 and Daniel S. Wechsler1*

1Division of Pediatric Hematology-Oncology, Department of Pediatrics and Communicable Diseases, University of Michigan School of Medicine, Ann Arbor, Michigan
2Division of Urology, Department of Surgery, University of Michigan School of Medicine, Ann Arbor, Michigan

BACKGROUND. Mxi1, an antagonist of c-Myc, maps to human chromosome 10q24-q25, a region altered in a substantial fraction of prostate tumors. Mice deficient for Mxi1 exhibit significant prostate hyperplasia. We studied the ability of Mxi1 to act as a growth suppressor in prostate tumor cells.

METHODS. We infected DU145 prostate carcinoma cells with an Mxi1-expressing adenovirus (AdMxi1) in vitro, and measured Mxi1 expression, cell proliferation, soft agar colony formation, and cell cycle distribution. To explore mechanisms of Mxi1-induced growth arrest, we performed gene expression analysis.

RESULTS. AdMxi1 infection resulted in reduced cell proliferation, reduced soft agar colony formation, and a higher proportion of cells in the G2/M phase of the cell cycle. This G2/M growth arrest was associated with elevated levels of cyclin B, and reduced levels of c-MYC and MDM2.

CONCLUSIONS. The ability of AdMxi1 to suppress prostate tumor cell proliferation supports a role for Mxi1 loss in the pathogenesis of a subset of human prostate cancers.


KEY WORDS: prostate cancer; chromosome 10; c-Myc; adenovirus; G2/M arrest

INTRODUCTION

Prostate cancer is the most common cancer in men, and is associated with significant morbidity and mortality. Approximately 200,000 cases of prostate cancer are diagnosed and almost 40,000 men die from prostate cancer in the United States each year [1]. Genetic alterations that contribute to the pathogenesis of prostate tumors include activation of oncogenes and inactivation of tumor suppressor genes. Characteristic gains and losses of chromosomal material, which likely include such genes, are also seen in many cases of prostate cancer [2].

Amplification or overexpression of the c-MYC oncogene in many human prostate adenocarcinomas has implicated it in the pathogenesis and progression of prostate cancer [3–7]. Furthermore, c-MYC, which encodes a transcription factor of the basic helix-loop-helix/leucine zipper (bHLH/ZIP) family [8,9], is amplified, rearranged, or overexpressed in human prostate cancer cell lines [10-13]. Retrovirally mediated expression of MYC in combination with activated RAS in the mouse urogenital sinus causes a high frequency

Grant sponsor: American Society for Clinical Oncology; Grant sponsor: Strokes Against Cancer Foundation; Grant sponsor: NICHD Child Health Research Center; Grant number: 1-P30-HD28820-01; Grant sponsor: NCI; Grant number: 1-P50-CA69568S and 1-P01-CA75136-01A1; Grant sponsor: Howard Hughes Medical Institute; UM–Comprehensive Cancer Center NIH; Grant number: CA46592; Grant sponsor: UM–Multipurpose Arthritis Center NIH; Grant number: AR20557; Grant sponsor: UM–BRCF Core Flow Cytometry Facility.

*Correspondence to: Daniel S. Wechsler, MD, PhD, Section of Pediatric Hematology-Oncology, The University of Michigan, 1500 E. Medical Center Drive, CCGC 4312, Ann Arbor, Michigan 48109. E-mail: dwechsl@umich.edu

Received 31 July 2000; Accepted 18 January 2001
of poorly differentiated prostate cancers in such mice [14]. Chronic overexpression of c-MYC in transgenic murine ventral prostate epithelial cells leads to the development of epithelial cell abnormalities similar to those seen in low-grade prostatic intraepithelial neoplasia in humans [15]. Finally, introduction of c-MYC antisense transcripts or oligonucleotides into human prostate cell lines both in vitro and in vivo results in reduced cell viability and tumor size [16,17]. Although the overall contribution of c-MYC to prostate cancer development and progression remains uncertain [18], these findings clearly implicate increased c-MYC expression in prostate cancer pathogenesis.

Mxi1 opposes the growth-promoting activity of c-Myc by repressing transcription of c-Myc-activated target genes [23-26]. Mxi1 inhibits the ability of c-Myc to transform cells in vitro [23,27,28], and its expression is associated with cellular differentiation [20,29-31]. By counteracting c-Myc, Mxi1 functions as a growth suppressor, resulting in reduced cell proliferation in vitro [32]. If c-MYC overexpression plays a role in the pathogenesis of prostate malignancies, inactivation or loss of MXI1 might enhance the proliferative effect of c-Myc and contribute to prostate tumor pathogenesis.

Several lines of evidence point to a role for Mxi1 as a potential growth suppressor in the prostate. Transfection of whole chromosome 10 to PC3 prostate cancer cells reduces the tumorigenicity of these cells [33,34], indicating the existence of growth suppressive gene(s) on chromosome 10. We [35] and others [36,37] previously localized the human MXI1 gene to chromosome 10q24-25. Deletions resulting in loss of alleles in this region of chromosome 10 are observed in 30-50% of human prostate tumors [18,38-42]. Furthermore, inactivating mutations in the MXI1 coding sequence have been described in some primary human prostate tumors [43,44]. Finally, mxil-knockout mice, which have a tumorigenic phenotype, demonstrate striking prostate hyperplasia [45]. The enhanced proliferation of prostate epithelium in mice that lack Mxi1 indicates a role for Mxi1 in normal prostate development, and suggests its potential involvement in human prostate neoplasia.

To better define the function of MXI1 in prostate carcinoma, we have examined the ability of an Mxi1-expressing adenovirus to suppress human prostate cancer cell proliferation. Our demonstration that Mxi1 expression results in markedly decreased proliferation of DU145 prostate cells indicates a role for Mxi1 as a prostate growth suppressor, and supports the hypothesis that loss of Mxi1 activity plays a role in the pathogenesis of a subset of human prostate cancers.

MATERIALS AND METHODS

Cells

DU145 cells, originally derived from a prostate carcinoma brain metastasis, were obtained from the American Type Culture Collection (ATCC, Rockville, MD). DU145 cells are androgen-insensitive, and can form colonies in soft agar [46]. Furthermore, these cells have enhanced expression of c-MYC, as well as loss of chromosome 10q [47], and do not have detectable levels of MXI1 mRNA by Northern blot (Taj and Wechsler, unpublished observations). Cells were maintained in RPMI 1640 (Gibco BRL, Rockville, MD) with 10% heat inactivated fetal bovine serum (HIFBS), 1% penicillin/streptomycin and 1% L-glutamine, and grown in 5% CO2 at 37°C.

Adenovirus Preparation, Infection, and Optimization

We cloned the human MXI1 cDNA into pAdRSV4 [48] to generate a human Mxi1-expressing adenovirus (AdMxi1). The pAdRSV4 plasmid includes a constitutive Rous Sarcoma Virus (RSV) promoter to ensure high levels of expression, in an E1-deleted adenovirus backbone. Since reliable, commercial anti-Mxi1 antibodies are not available, we modified the MXI1 cDNA at its C-terminal end to contain coding sequence for an influenza hemagglutinin (HA) peptide epitope (YPYDVPDYA). This HA-tagged protein could then be detected using anti-HA antibodies. After DNA sequencing to confirm appropriate sequence and orientation of the MXI1-HA cDNA, replication-incompetent AdMxi1 was prepared by the Virus Core Facility at The University of Michigan, with confirmatory PCR and western blot analysis performed at each step. AdMxi1 was concentrated to a titer of 1 × 1012 particles/ml, and had a replication competent adenovirus (RCA) content of less than 10-9. Control viral preparations included AdLacZ (containing the bacterial β-galactosidase gene), and AdΔE1 ("empty" virus with a deleted E1 region), both at titers of 1 × 1012 particles/ml. The titer of plaque forming units (pfu) for each virus was estimated to be 1% of the particle number.

Twenty-four hours before viral infection, 105 DU145 cells were plated in wells of a 6-well plate. AdMxi1, AdLacZ or AdΔE1 viral particles were suspended in RPMI (with 1% penicillin/streptomycin (p/s) and 1% glutamine (glut) but no HIFBS). Following aspiration
of media from the cells, the viral suspension was added in a total volume of 2 ml. After a 2 hr incubation, the medium was replaced with RPMI containing 5% HIFBS, 1% p/s, and 1% glut. Medium containing 10% HIFBS was replaced 16–18 hr later and every 2–3 day subsequently. To determine the optimal titer for viral infection, DU145 cells were plated in wells of 24-well plates, and infected with a range of AdLacZ titers (MOI (multiplicity of infection) of 10–5000 pfu/cell). Twenty-four hours after infection, cells were washed, fixed with 2% formaldehyde/0.05% glutaraldehyde in PBS, and exposed to the substrate X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside; Gibco BRL) at a concentration of 1 mg/ml in PBS with 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgCl₂. After X-gal treatment, expression of β-galactosidase results in a blue color, providing a visual measure of the infection efficiency. More than 95% of cells were blue at AdLacZ titers greater than 500 pfu/cell, while uninfected DU145 cells showed no color. Experiments were done at titers of 1250–1750 pfu/cell, since lower titers of either virus (500–1000 pfu/cell) yielded inconsistent differences in growth rate, whereas higher titers (>2500 pfu/cell) resulted in nonspecific toxicity and reduced cell number (Taj and Wechsler, unpublished observations). Because effects of AdLacZ were essentially identical to those seen with AdΔE1, only results for infection with AdΔE1 as a negative control will be presented for clarity.

Western Blot Analysis, Immunofluorescence, and Confocal Microscopy

DU145 cells were plated in 6-well plates at a concentration of 70,000 cells/well. After 24 hr, cells were infected by AdMxi1 at MOI’s of 1,000–10,000 pfu/cell. Ninety-six hours following infection, cells were harvested, washed, and subjected to three freeze-thaw cycles. Protein lysates were sonicated, normalized for total protein concentration, mixed with equal volumes of 2× loading buffer, and boiled for 10 min at 95°C. Samples were electrophoresed on a 12% acrylamide SDS gel, followed by transfer to PVDF membrane (Bio-Rad, Hercules, CA). Mxi1-HA protein was detected with a rabbit polyclonal anti-HA antibody (Santa Cruz Biotechnology, Santa Cruz, CA), followed by goat anti-rabbit IgG HRP (Jackson Immunoresearch Laboratories, West Grove, PA). An HA-tagged Bcl-xS protein (gift of G. Nunez) was used as a positive control for the HA antibody, and an expected band of approximately 22 kDa was observed (data not shown). The Enhanced Chemiluminescence (ECL; Amersham-Pharmacia, Buckinghamshire, England) system was used for detection according to manufacturer’s instructions.

For microscopy studies, DU145 cells were grown on glass cover slips coated with 0.01% poly-l-lysine (Sigma, St. Louis, MO). After 24 hr, cells were infected with AdMxi1 or AdLacZ. Two to four days after infection, cells were cooled on ice for 10 min, washed twice with PBS, and permeabilized with methanol for 7 min at −20°C. After washing twice with PBS at 4°C, cells were incubated for 1 hr with a 1:100 dilution of mouse monoclonal anti-HA antibody (12CA5; Roche, Indianapolis, IN). Following three PBS washes, a 1:50 dilution (in PBS) of secondary antibody (fluorescein-conjugated, goat anti-mouse IgG; Roche) was added to the cells for 1 hr. After three additional PBS washes, Vectashield Mounting Medium (Vector Labs, Burlingame, CA) was applied. Immunofluorescence microscopy was performed using a Nikon Eclipse E600 immunofluorescence microscope. Confocal laser scanning microscopy was performed using a Bio-Rad MRC600 confocal microscope in the Cell Biology Laboratories Core Facility at The University of Michigan.

Soft Agar Clonogenic Assay

The ability of uninfected and virally infected DU145 cells to form colonies in soft agar was determined by minor modification of a previously described procedure [32]. Briefly, a 1:1 mixture of SeaPlaque agarose and SealKem ME agarose (FMC Bioproducts, Rockland, ME) was used. A 1.4% bottom layer of agarose in RPMI medium (with HIFBS, penicillin/streptomycin, and l-glutamine) in a 100 mm plate was overlaid with 10⁵ infected or uninfected DU145 cells resuspended in 0.8% agarose with RPMI (and additives). Tissue culture medium was added atop the agarose layer, and plates were incubated at 37°C in 5% CO₂. Medium was replaced every 3–4 days to prevent drying. Colonies were enumerated 14–21 days later. The soft agar assay was performed three times, with duplicate samples in each assay.

BrdU Incorporation Assay

DU145 cells (5 × 10⁵ cells/well in a 96-well plate) were infected in triplicate with increasing concentrations of AdMxi1 and AdLacZ viruses as described above. After 48 hr, 110 μl of BrdU labeling reagent (1:1,000 dilution; Roche) was added to each well, and cells were incubated for 2 hr at 37° in 5% CO₂. The labeling reagent was then replaced with 200 μl of fixing/denaturing solution, and cells were incubated for 30 min at 25°C. Next, 100 μl of peroxidase-conjugated anti-BrdU antibody (1:100 dilution; Roche) was added, with incubation for 90 min at 25°C. Cells were washed three times, 100 μl of substrate solution were added, and cells were incubated for 30 min at
25°C. Absorbances were first measured at 370 nm (reference wavelength 492 nm) with a SpectraMax ELISA Plate Reader (Molecular Devices, Sunnyvale, CA). After stopping the reactions with 25 μl of 1 M H2SO4, absorbances were read at 450 nm (reference wavelength 690 nm).

**Flow Cytometry**

To evaluate DNA content and expression of Mxi1-HA in infected DU145 cells, 100–400,000 cells were washed in wash buffer (WB: phosphate buffered saline pH 7.2 (PBS)/1% heat-inactivated fetal bovine serum), and fixed with 75% ice-cold ethanol for 2 hr at −20°C. Cells were washed with WB, suspended in 0.25% Triton X-100 in WB for 5 min at 4°C, washed again, and resuspended at a concentration of 10^7 cells/ml. Primary antibody (1:500 rabbit anti-HA (Roche)) was added for 30 min at 25°C, followed by washing with WB. Secondary antibody (donkey anti-rabbit IgG/Cy3 (Jackson Immunoresearch Laboratories)) was added for a 30 min, 25°C incubation, followed by washing with WB. Cell pellets were resuspended in propidium iodide solution (10 μg/ml in PBS) and incubated for a minimum of 10 min. Flow cytometry analysis for DNA content and fluorescence was performed at the University of Michigan Flow Cytometry Core Facility with a Coulter Elite ESP Cell Sorter and accompanying analysis software.

**Gene Expression Profiling**

The expression levels of cell cycle related genes were evaluated in AdMxi1 infected cells using the GEArray nylon membrane cDNA miniaarray System (SuperArray, Bethesda, MD) according to manufacturers instructions. Briefly, mRNA was harvested from AdMxi1- and AdΔE1-infected cells with an Oligotex Direct mRNA Kit (Qiagen, Valencia, CA). After RNA quantitation, cDNA probes were prepared by RT-PCR using GEA primer mix, [α-32P] dCTP and MMLV Reverse Transcriptase. Following prehybridization, labeled cDNA probes were hybridized to Pathwayfinder-1 and Cellcycle-1 GEArray membranes at 68°C for 24 hr. After washing, relative transcript abundance was detected with a Molecular Dynamics Storm phosphorimager and quantitated using NIH Image. Hybridizations with each cDNA probe were performed twice.

**Statistical Analysis**

The two-tailed Student t test was used to assess statistical significance of differences among experimental groups. Probability values of *P* < 0.05 were considered statistically significant.

---

**RESULTS**

**Exogenous Mxi1 Expression in DU145 Human Prostate Cancer Cells**

We assessed the effects of restoring Mxi1 expression to DU145 prostate cancer cells that lack functional Mxi1 expression. To avoid the inefficiency and selection bias associated with plasmid transfection, and to achieve high-level MXI1 expression in a large percentage of cells, we constructed an E1-deleted (ΔE1), replication-incompetent MXI1-expressing adenovirus (AdMxi1). An empty E1-deleted adenovirus (AdΔE1) was used to control for adenoviral infection.

Mxi1-HA protein expression in AdMxi1-infected DU145 cells was assessed by Western blot analysis using an anti-HA antibody. A 36-kDa band corresponding to the size of Mxi1-HA was seen in AdMxi1-infected cell extracts at an MOI of 1,000 pfu/cell (Fig. 1, lane 3). The intensity of this band is not increased when 5,000 pfu/cell are used for infection (lane 4). A band of reduced intensity is seen when as few as 300 pfu/cell were used for infection (Taj and Wechsler, unpublished observations). This HA-specific band is not present in control AdΔE1-infected cells (lane 2), or in uninfected control cells (data not shown). Immunofluorescence microscopy was used to localize the Mxi1-HA protein within infected cells. AdMxi1-infected cells exhibited some cytoplasmic expression and a pronounced speckled pattern of nuclear staining, consistent with the presence of Mxi1 in the nucleus (Fig. 2a). Higher power visualization by confocal laser microscopy confirmed the clumped distribution of nuclear Mxi1-HA in AdMxi1-infected

![Fig. 1](image-url) A 36 kDa Mxi1-HA protein is expressed in AdMxi1-infected DU145 cells. **Lane 1**, in vitro translated (IVT) Mxi1-HA protein; **Lane 2**, cell lysate prepared from DU145 cells infected three days previously with AdΔE1; **Lanes 3 and 4**, cell lysates prepared from DU145 cells infected three days previously with AdMxi1 at the indicated titers. Mxi1-HA protein expression was detected by western blot analysis using a rabbit anti-HA antibody. Mobility of 42 and 31 kDa markers are indicated.
No staining was seen in uninfected or AdΔE1-infected cells. These studies indicate that AdMxi1 infection of DU145 cells results in strong expression of Mxi1 protein and transport into the nucleus, where the distribution is consistent with chromatin binding and presumably transcriptional repression activity. The degree of high-level Mxi1-HA expression in infected cells was confirmed by flow cytometry with rabbit anti-HA antibodies, which demonstrated that 75–80% of the AdMxi1-infected cells express Mxi1-HA (see Fig. 5d).

**DU145 Proliferation Is Suppressed by Adenoviral Mxi1**

Mxi1 expression in DU145 cells by AdMxi1 infection is associated with a marked reduction in growth rate in vitro (Fig. 3). Uninfected DU145 cells (Fig. 3a) and control adenoviral vector AdΔE1-infected cells (Fig. 3b) double their numbers in 24 and 48 hr, respectively, while AdMxi1-infected cells (Fig. 3b) exhibit no appreciable proliferation up to 7 days following infection. On any given day (except day 0), uninfected DU145 cell counts were consistently 1.5–3 times greater than AdΔE1-infected cell numbers, indicating some nonspecific adenovirus-associated toxicity. The growth inhibitory effect of AdMxi1 was apparent and significantly different \((P<0.003)\) from AdΔE1 by the third day postinfection. The growth of AdMxi1-infected cells remained suppressed through day 7 (Fig. 3). After 7 days, a subset of AdMxi1-infected cells began to grow at rates comparable to AdΔE1-infected cells, becoming confluent after 10–13 days. The AdMxi1-infected cells that escaped from growth inhibition showed no residual Mxi1 expression by Western blot (data not shown).

A BrdU incorporation assay was performed to determine whether the increased doubling time of AdMxi1-infected cells was due to reduced cell proliferation. As shown in Figure 4, DU145 cells infected with AdMxi1 show a statistically significant decrease in BrdU incorporation, compared with AdΔE1-infected cells, at all viral titers tested.

To examine the potential of virally infected DU145 cells to form anchorage-independent colonies (a measure of their transformation potential), cells were grown in soft agar. The number of soft agar colonies derived from uninfected DU145 cells was 285 (range 264–308). AdΔE1-infected cells yielded 119 colonies (range 108–136), consistent with nonspecific adenoviral toxicity \((P=0.0004)\). Notably, the number of colonies derived from AdMxi1-infected cells was significantly reduced by nearly 75%, to 31 colonies (range 28–36), in comparison with AdΔE1-infected cells \((P=0.0007)\).

**Adenoviral Mxi1 Infection of DU145 Cells Results in G2/M Arrest**

To investigate the mechanism of reduced cell proliferation associated with MXII expression, the cell cycle distributions of control AdΔE1- and AdMxi1-infected DU145 cells were compared. In the control AdΔE1-infected DU145 cells, more than half of the
cells are in G0/G1, 30.4% are in S phase, and 15.2% are in G2/M (Fig. 5a). The profile of uninfected DU145 cells is similar to that shown for Ad\(\Delta\)E1-infected cells, with similar percentages of cells in G0/G1 (58.1%; \(P \leq 0.10\)), S (22.8%; \(P \leq 0.12\)), and G2/M (19.1%; \(P \leq 0.17\)). In contrast, in AdMxi1-infected DU145 cells, a significantly lower proportion (30.9%) are in G0/G1 (\(P \leq 0.0006\) compared with Ad\(\Delta\)E1), with a corresponding relative increase in the number of cells in S phase (37.6%; \(P = 0.04\)) and G2/M (31.5%; \(P = 0.01\)), suggesting that AdMxi1 infection of DU145 cells results in a G2/M block, as we have previously shown in glioblastoma cells [32]. AdMxi1 does not appear to induce apoptosis, since there is no increase in the number of sub-G0/G1 cells. To confirm the lack of AdMxi1-induced apoptosis, we performed a TUNEL assay with uninfected, Ad\(\Delta\)E1-infected, and AdMxi1-infected DU145 cells. Using this light microscopy-based qualitative technique, no significant apoptosis was detected in either uninfected or infected DU145 cells: fewer than 5% of cells demonstrated evidence of apoptosis under all three conditions.

Since cyclin B regulates progression through G2/M, we hypothesized that Mxi1 might alter the level of cells are in G0/G1, 30.4% are in S phase, and 15.2% are in G2/M (Fig. 5a). The profile of uninfected DU145 cells is similar to that shown for Ad\(\Delta\)E1-infected cells, with similar percentages of cells in G0/G1 (58.1%; \(P = 0.10\)), S (22.8%; \(P = 0.12\)), and G2/M (19.1%; \(P = 0.17\)). In contrast, in AdMxi1-infected DU145 cells, a significantly lower proportion (30.9%) are in G0/G1 (\(P \leq 0.0006\) compared with Ad\(\Delta\)E1), with a corresponding relative increase in the number of cells in S phase (37.6%; \(P = 0.04\)) and G2/M (31.5%; \(P = 0.01\)), suggesting that AdMxi1 infection of DU145 cells results in a G2/M block, as we have previously shown in glioblastoma cells [32]. AdMxi1 does not appear to induce apoptosis, since there is no increase in the number of sub-G0/G1 cells. To confirm the lack of AdMxi1-induced apoptosis, we performed a TUNEL assay with uninfected, Ad\(\Delta\)E1-infected, and AdMxi1-infected DU145 cells. Using this light microscopy-based qualitative technique, no significant apoptosis was detected in either uninfected or infected DU145 cells: fewer than 5% of cells demonstrated evidence of apoptosis under all three conditions.

Since cyclin B regulates progression through G2/M, we hypothesized that Mxi1 might alter the level of...
cyclin B in comparison with controls, and that altered cyclin B function might be the mechanism for the observed G2/M block in AdMxi1-infected DU145 cells. Two-color flow cytometric analysis was used to examine the relationship between Mxi1 and cyclin B expression in AdMxi1-infected cells. As indicated in Figure 5, 46% of control AdΔE1-infected cells express cyclin B with only a 5% background of HA-positive cells. In contrast, 63% of AdMxi1-infected cells express cyclin B, and of these, the majority are also positive for Mxi1-HA expression. Cyclin B is detectable in 76% of AdMxi1-infected HA-positive cells (double positives, quadrant 2), but in only 13% of AdMxi1-infected HA-negative cells (quadrant 4). The data shown are from one representative experiment (of six performed); percentages quoted in the text of Results are means (± SEM) from six individual experiments.

Finally, as a starting point to explore other possible downstream effectors of Mxi1-induced growth arrest, we surveyed the levels of expression of a panel of cell cycle-related genes in DU145 cells infected by AdMxi1 in comparison with AdΔE1. With RNA from cells infected 48 hr previously, densitometric analysis revealed decreases in the intensity of both c-MYC (by 24%) and MDM2 (by 26%) expression. Although the decreases in c-MYC and MDM2 are relatively modest, they are highly reproducible. In contrast, only minor changes were observed with other genes in the panel (e.g., p53, p21, gadd45) for which no significant alterations were detected. The changes in these patterns of expression were not observed when samples taken 120 hr postinfection were used (data not shown). Taken together, these observations suggest that Mxi1-induced...
suppression of proliferation is mediated, at least in part, by well-established regulators of the cell cycle.

**DISCUSSION**

Several lines of evidence suggest a potential role for Mxl1 as a prostate growth suppressor. First, Mxl1 antagonizes c-Myc [23–28], which is overexpressed in many cases of prostate cancer [3–7]. Second, deletions or rearrangements of the chromosome 10 region to which the MXII gene maps are common in primary prostate tumors [18,38–42]. While PTEN/MMAC1 [49,50], a chromosome 10q tumor suppressor gene, is thought to play a fundamental role in prostate cancer development, the relative proximity of MXII to PTEN/MMAC1 suggests that concomitant MXII allelic loss might play a cooperative role in prostate tumor pathogenesis. Third, MXII coding sequence mutations have been described in two separate series of prostate tumors [43,44]. Finally, mxi1 knockout mice [45] exhibit abnormally hypertrophic prostate glands, with foci of enlarged and complex glandular structures, hypercellular acini, dysplastic cells, and occasional mitotic figures, supporting the notion that Mxi1 plays a role in prostate development. Although they display no overt prostate neoplastic changes, these mice do spontaneously develop malignant lymphomas, indicating that Mxi1 may play a role as a tumor suppressor gene in vivo [51]. The ability of Mxi1 to ‘balance’ and antagonize the activity of c-Myc, and the resultant increased, relatively unopposed c-Myc activity in mxi1 knockout mice may contribute to these changes. The goal of the present study was to test the effectiveness of an Mxi1-expressing adenovirus in reducing proliferation of prostate tumor cells in vitro.

We previously demonstrated the ability of Mxi1 to suppress growth of glioblastoma cells using an inducible plasmid expression vector [32]. In the present studies in human prostate cells, we used an adenovirus vector containing the MXII cDNA to infect DU145 cells. Because of the lack of an effective anti-Mxi1 antibody, we tagged Mxi1 with an influenza hemagglutinin (HA) peptide epitope to enable detection; since results similar to those using a native Mxi1 protein were obtained [32], the presence of a C-terminal HA moiety apparently does not interfere with Mxi1 function. Using AdMxi1, we achieved an infection efficiency of 90–95%, with 75–80% of cells expressing Mxi1 protein in the nucleus 48 hr after infection. Enhanced Mxi1 expression led to a significant reduction in growth rate during the first week post-infection. After 7 days, AdMxi1-infected cells tended to grow at rates comparable to AdΔE1-infected cells, and after 10–13 days, confluent AdMxi1-infected cells showed no residual Mxi1 expression by western blot. The mechanism of outgrowth of Mxi1-HA negative cells is not known. While the outgrowth might be due to the recovery and emerging predominance of a minimal subset of uninfected cells, it could also be related to loss of the ability of infected cells to express the Mxi1-HA protein, perhaps by promoter methylation.

AdMxi1 infection of DU145 prostate carcinoma cells led to a nearly 75% reduction in the number of colonies in soft agar when compared to colonies from cells infected with the control AdΔE1 adenovirus. Since anchorage-independent growth in soft agar correlates with tumorigenicity in vivo, this finding indicates that Mxi1 suppresses factors necessary for tumor production. There was also a reduction in BrdU incorporation in AdMxi1-infected cells that correlated with the reduced proliferation induced by AdMxi1. The observed reduction in proliferation was not due to apoptosis, since we did not detect an increase in the sub-G0/G1 peak by flow cytometry or in apoptotic nuclei using the TUNEL assay. However, using flow cytometry, we did detect an increased proportion of cells in the S and G2/M phases of the cell cycle. This observation of a G2/M arrest as one possible mechanism by which MXII suppresses proliferation is intriguing, since we saw a similar Mxi1-dependent effect in a completely different cell line (U87MG glioblastoma) using a different method of expression (transfection with an inducible MXII plasmid) of a non-HA-tagged Mxi1 protein [32]. Notably, this effect on the cell cycle is different from that produced with the highly homologous Mad1 protein [52], suggesting that these Myc antagonists may have different gene targets.

In investigating the mechanism of the G2/M arrest, we found increased levels of cyclin B after adenoviral Mxi1 expression. Dephosphorylation of cyclin B is required for transition through the G2/M phase of the cell cycle. Perturbation of normal cyclin B levels in the setting of Mxi1 overexpression may prevent exit from this stage of the cell cycle. Indeed, elevated levels of cyclin B have been described in G2/M arrest [53,54]. It is not known whether Mxi1 expression directly results in increased cyclin B expression, or whether cyclin B is elevated indirectly as a result of the G2/M block. The specific mechanisms for increased cyclin B expression (e.g., whether it is transcriptionally or posttranscriptionally mediated) remain to be elucidated. In addition, we observed reduced levels of c-MYC and MDM2 after adenoviral Mxi1 expression. The observed reduction in c-MYC mRNA expression is consistent with the previously described direct transcriptional repression of the c-Myc promoter by Mxi1 [55]. Since c-Myc overexpression promotes proliferation and transition through G2/M, reduced c-Myc as seen in
AdMxi1-infected cells may inhibit this progression. Indeed, many of the effects of Mxi1 may result from direct or indirect misregulation of c-Myc. Finally, since Mdm2 negatively regulates p53-mediated growth suppression, Mxi1-induced downregulation of MDM2 might enhance p53-mediated growth suppression [56,57]. Whether this is a direct (i.e., transcriptional) effect of Mxi1 overexpression, or merely a reflection of an ongoing G2/M block is unclear at the present time. The absence of changes in these patterns of expression by 120 hr after infection with AdMxi1 may be attributable to transcriptional repression by Mxi1 that occurs during a relatively short window of time. Alternatively, a population of cells with reduced Mxi1 expression may already begin to appear at this time.

Alterations in levels of other cell cycle proteins in the presence of Mxi1 overexpression remain to be evaluated. For example, since c-Myc activates transcription and expression of the cdc25A CDK-activating phosphatase [58], downregulation of this protein by Mxi1 might also contribute to the observed cell cycle arrest. Nevertheless, Mxi1-induced alterations in cyclin B, c-Myc, and Mdm2 indicate their potential involvement in G2/M growth arrest.

CONCLUSIONS

Prostate cancer, which is most common in later life, arises as a result of a multistep process of oncogene-activating and tumor suppressor gene-inactivating events. It is likely that a number of cooperating genetic lesions contribute to tumor development, with possible involvement of Mxi1 in a subset of tumors. Whether Mxi1 is involved early or late in the process is presently unknown. We have demonstrated prostate cancer cell growth inhibition by AdMxi1, with resultant G2/M arrest, associated with increased expression of cyclin B and reduced expression of c-Myc and Mdm2. These findings indicate a growth suppressor role for Mxi1 in prostate cancer. The ability of adenovirus-mediated Mxi1 expression to reduce DU145 prostate cell proliferation provides a rationale for future studies to develop in vivo methods of Mxi1 delivery as a strategy for reducing malignant prostate cancer growth and progression.

ACKNOWLEDGMENTS

We thank K. Cherian (University of Michigan Adenovirus Core) for help in viral production, and M. KuKurugu (University of Michigan Flow Cytometry Core) for assistance in flow cytometry analysis. We appreciate the constructive input of L. Benson, T. Carey, C. Dang, G. Nunez, K. Pienta, S. Wechsler, and R. Wechsler-Reya.

This study was supported in part by An American Society for Clinical Oncology Young Investigator Award, the Strokes Against Cancer Foundation, NICHD Child Health Research Center Grant 1-P30-HD28820-01, and NCI Prostate SPORE 1-P50-CA69568S (to D.S.W.); a Howard Hughes Medical Institute Research Training Fellowship for Medical Students (to C.H.); an American Society for Clinical Oncology Career Development Award, and NCI 1-PO1-CA75136-01A1 (to M.G.S.); and by the UM–Comprehensive Cancer Center NIH CA46592, the UM–Multipurpose Arthritic Center NIH AR20557 and the UM–BRCF Core Flow Cytometry facility.

REFERENCES


51. Foley KP, Eisenman RN. Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim Biophys Acta 1999;1423:M37–47.


